AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19714953 — intervention group
Group type: EXPERIMENTAL
Intervention: Head and neck surgical oncology clinical practicum (Experimental Group, n=19)
Number of subjects: 37
Study 19714953 — intervention group
Group type: COMPARATOR
Intervention: General surgical unit (Control Group, n=18)
Number of subjects: 37
Study 17556718 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) for 4 months
Number of subjects: 24
Study 17556718 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control) for 4 months
Number of subjects: 24
Study 15218357 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin and Cyclophosphamide (EC)
Number of subjects: 103
Study 15218357 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (ET)
Number of subjects: 103
Study 15218357 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease of HER-2/neu ECD levels after three courses of therapy
Number of subjects: 103
Study 11345180 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive protein hydrolysate preterm formula (EH)
Number of subjects: 61
Study 11345180 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial protein hydrolysate preterm formula (PH)
Number of subjects: 61
Study 11345180 — intervention group
Group type: COMPARATOR
Intervention: Standard preterm formula (SF)
Number of subjects: 61
Study 11345180 — intervention group
Group type: COMPARATOR
Intervention: Fortified breast milk (FBM)
Number of subjects: 61
Study 9641650 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole alone
Number of subjects: 23
Study 9641650 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole and amoxycillin
Number of subjects: 23
Study 7743368 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of nitrite/nitrate (NO2/NO3) in septic patients
Number of subjects: 0
Study 7743368 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of NO2/NO3 with tumor necrosis factor alpha
Number of subjects: 0
Study 7743368 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of NO2/NO3 with interleukin 6
Number of subjects: 0
Study 7743368 — intervention group
Group type: EXPERIMENTAL
Intervention: Body core temperature correlation with NO2/NO3 levels
Number of subjects: 0
Study 2700362 — intervention group
Group type: EXPERIMENTAL
Intervention: PT-01
Number of subjects: 0
Study 2700362 — intervention group
Group type: EXPERIMENTAL
Intervention: S + A (PT-01 treatment combined with scaling)
Number of subjects: 0
Study 792640 — intervention group
Group type: EXPERIMENTAL
Intervention: Mazindol (AN 448)
Number of subjects: 28
Study 792640 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo or no treatment)
Number of subjects: 28
Study 30347119 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention delivered by text message
Number of subjects: 0
Study 30347119 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 27989399 — intervention group
Group type: EXPERIMENTAL
Intervention: End-of-life communication intervention
Number of subjects: 376
Study 27989399 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 376
Study 25935412 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-smoker
Number of subjects: 1374
Study 25935412 — intervention group
Group type: COMPARATOR
Intervention: Smoker
Number of subjects: 1374
Study 23442897 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical behaviour therapy
Number of subjects: 180
Study 23442897 — intervention group
Group type: EXPERIMENTAL
Intervention: General psychiatric management
Number of subjects: 180
Study 23442897 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline number of suicide attempts
Number of subjects: 180
Study 23442897 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of childhood sexual abuse
Number of subjects: 180
Study 23442897 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of hospitalizations in the 4 months prior to study entry
Number of subjects: 180
Study 21402982 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of autologous plasmin enzyme (APE), 0.2 mL
Number of subjects: 8
Study 18945594 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem
Number of subjects: 403
Study 18945594 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 403
Study 17038056 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal dose of 1% chlorhexidine gel
Number of subjects: 157
Study 17038056 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of chlorhexidine gel and whitening dentifrice
Number of subjects: 157
Study 17038056 — intervention group
Group type: COMPARATOR
Intervention: Standard fluoride paste
Number of subjects: 157
Study 12921007 — intervention group
Group type: EXPERIMENTAL
Intervention: lifestyle physical activity intervention (group-based)
Number of subjects: 244
Study 12921007 — intervention group
Group type: EXPERIMENTAL
Intervention: lifestyle physical activity intervention (telephone and mail-delivered)
Number of subjects: 244
Study 11034509 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal anaesthesia with 0.25% bupivacaine
Number of subjects: 60
Study 11034509 — intervention group
Group type: COMPARATOR
Intervention: Standardized general anaesthetic (control group)
Number of subjects: 60
Study 9068264 — intervention group
Group type: COMPARATOR
Intervention: 50 mg/day atenolol
Number of subjects: 56
Study 9068264 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/day celiprolol
Number of subjects: 56
Study 9068264 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg/day isosorbide dinitrate
Number of subjects: 56
Study 9068264 — intervention group
Group type: EXPERIMENTAL
Intervention: celiprolol
Number of subjects: 56
Study 9068264 — intervention group
Group type: EXPERIMENTAL
Intervention: isosorbide dinitrate
Number of subjects: 56
Study 9068264 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 56
Study 8446440 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (4 mg)
Number of subjects: 10
Study 8446440 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 10
Study 3462014 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladosporium herbarum inhalation (1:100000, 1:10000, 1:1000, 1:100 w/v)
Number of subjects: 5
Study 3462014 — intervention group
Group type: COMPARATOR
Intervention: Saline inhalation
Number of subjects: 5
Study 3462014 — intervention group
Group type: COMPARATOR
Intervention: Histamine inhalation (0.3, 0.6, 1.2, 2.4 mg/ml)
Number of subjects: 5
Study 3462014 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladosporium herbarum inhalation
Number of subjects: 5
Study 3462014 — intervention group
Group type: COMPARATOR
Intervention: Histamine inhalation
Number of subjects: 5
Study 31694978 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical Anorexia Nervosa (AAN)
Number of subjects: 116
Study 31694978 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower heart rate (HR)
Number of subjects: 116
Study 31694978 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower serum phosphorus
Number of subjects: 116
Study 31694978 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight and menstrual history
Number of subjects: 116
Study 28857203 — intervention group
Group type: EXPERIMENTAL
Intervention: Total pulpectomy (TP)
Number of subjects: 66
Study 28857203 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial pulpectomy (PP)
Number of subjects: 66
Study 28857203 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulpotomy (P)
Number of subjects: 66
Study 26474268 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational video presentation (group V, N=21)
Number of subjects: 42
Study 26474268 — intervention group
Group type: COMPARATOR
Intervention: Standard care (verbal information, group C, N=21)
Number of subjects: 42
Study 24605292 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-patient training program by cadaver dissection
Number of subjects: 5
Study 24605292 — intervention group
Group type: COMPARATOR
Intervention: Step-by-step training model on real patients
Number of subjects: 5
Study 22124840 — intervention group
Group type: EXPERIMENTAL
Intervention: Open donor nephrectomy
Number of subjects: 51
Study 22124840 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-sided transabdominal donor nephrectomy
Number of subjects: 51
Study 20229169 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g PSK plus 300 mg UFT
Number of subjects: 21
Study 20229169 — intervention group
Group type: COMPARATOR
Intervention: 300 mg UFT alone (control)
Number of subjects: 21
Study 20229169 — intervention group
Group type: EXPERIMENTAL
Intervention: PSK group
Number of subjects: 21
Study 20229169 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients analyzed
Number of subjects: 21
Study 20229169 — intervention group
Group type: EXPERIMENTAL
Intervention: PSK + UFT group
Number of subjects: 21
Study 17660032 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 800 IU of vitamin E alpha daily
Number of subjects: 27
Study 17660032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 15979439 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting TAXUS stent
Number of subjects: 61
Study 15979439 — intervention group
Group type: COMPARATOR
Intervention: Bare metal control stent
Number of subjects: 61
Study 12787300 — intervention group
Group type: EXPERIMENTAL
Intervention: cetirizine 10 mg
Number of subjects: 15
Study 12787300 — intervention group
Group type: EXPERIMENTAL
Intervention: fexofenadine 30 mg
Number of subjects: 15
Study 12787300 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study 12787300 — intervention group
Group type: EXPERIMENTAL
Intervention: cetirizine vs fexofenadine
Number of subjects: 15
Study 10383105 — intervention group
Group type: EXPERIMENTAL
Intervention: vancomycin/ceftriaxone
Number of subjects: 112
Study 10383105 — intervention group
Group type: COMPARATOR
Intervention: cefazolin
Number of subjects: 112
Study 10383105 — intervention group
Group type: EXPERIMENTAL
Intervention: vancomycin/gentamicin
Number of subjects: 112
Study 10383105 — intervention group
Group type: COMPARATOR
Intervention: cefazolin/gentamicin
Number of subjects: 112
Study 8876706 — intervention group
Group type: EXPERIMENTAL
Intervention: 320 mg Permixon
Number of subjects: 1098
Study 8876706 — intervention group
Group type: COMPARATOR
Intervention: 5 mg finasteride
Number of subjects: 1098
Study 1850811 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy after initial resection
Number of subjects: 81
Study 1850811 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy followed by resection
Number of subjects: 81
Study 1850811 — intervention group
Group type: COMPARATOR
Intervention: Combination of chemotherapy and radiotherapy (non-surgical patients)
Number of subjects: 81
Study 1850811 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection (overall surgical patients)
Number of subjects: 81
Study 1850811 — intervention group
Group type: COMPARATOR
Intervention: Postoperative chemotherapy only (for stage III patients)
Number of subjects: 81
Study 6218789 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine hydrochloride, 0.05 mg, orally twice daily for two weeks
Number of subjects: 0
Study 30332920 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin sensitivity testing before chemotherapy and during febrile neutropenia
Number of subjects: 30
Study 30332920 — intervention group
Group type: COMPARATOR
Intervention: Comparison to a control group of 30 age and sex matched patients with obesity
Number of subjects: 30
Study 30332920 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin sensitivity testing in patients with documented site of infection
Number of subjects: 30
Study 30332920 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall assessment of insulin sensitivity and hospitalization outcome
Number of subjects: 30
Study 30280582 — intervention group
Group type: EXPERIMENTAL
Intervention: Written consent
Number of subjects: 2027
Study 30280582 — intervention group
Group type: COMPARATOR
Intervention: Notification after enrollment
Number of subjects: 2027
Study 30280582 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief verbal consent
Number of subjects: 2027
Study 30280582 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost information
Number of subjects: 2027
Study 26810999 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily intravenous human albumin solution infusions for up to 14 days or until discharge, based on serum albumin levels.
Number of subjects: 80
Study 24495599 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support
Number of subjects: 46
Study 24495599 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual
Number of subjects: 46
Study 22218376 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intra-articular injection of 2.5 mL of low-molecular-weight, non-cross-linked hyaluronic acid
Number of subjects: 64
Study 22218376 — intervention group
Group type: COMPARATOR
Intervention: Single intra-articular injection of 2.5 mL of normal saline solution (placebo)
Number of subjects: 64
Study 20404227 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative dermoscopy
Number of subjects: 152
Study 20404227 — intervention group
Group type: COMPARATOR
Intervention: Clinical evaluation
Number of subjects: 152
Study 20404227 — intervention group
Group type: COMPARATOR
Intervention: Evaluation according to the ABCDEF rule
Number of subjects: 152
Study 20404227 — intervention group
Group type: COMPARATOR
Intervention: Dermoscopy of the nail plate
Number of subjects: 152
Study 17380530 — intervention group
Group type: EXPERIMENTAL
Intervention: Yttrium 90 ibritumomab tiuxetan
Number of subjects: 211
Study 15673841 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified constraint-induced therapy (mCIT)
Number of subjects: 10
Study 15673841 — intervention group
Group type: COMPARATOR
Intervention: Traditional rehabilitation (TR)
Number of subjects: 10
Study 11864865 — intervention group
Group type: EXPERIMENTAL
Intervention: LCP-supplemented formula
Number of subjects: 65
Study 11864865 — intervention group
Group type: COMPARATOR
Intervention: Formula without LCPs
Number of subjects: 65
Study 11864865 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 65
Study 10534462 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise program for 8 weeks followed by jogging, cycling, or swimming guided by target heart rate (n=315)
Number of subjects: 651
Study 10534462 — intervention group
Group type: COMPARATOR
Intervention: Control group maintaining normal routines without regular exercise (n=319)
Number of subjects: 651
Study 7777350 — intervention group
Group type: EXPERIMENTAL
Intervention: Canalith repositioning maneuver with mastoid vibration (n=27)
Number of subjects: 60
Study 7777350 — intervention group
Group type: EXPERIMENTAL
Intervention: Canalith repositioning maneuver without mastoid vibration (n=10)
Number of subjects: 60
Study 7777350 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment, n=23)
Number of subjects: 60
Study 7777350 — intervention group
Group type: EXPERIMENTAL
Intervention: Canalith repositioning maneuver with mastoid vibration (in a review of 67 patients)
Number of subjects: 60
Study 2407144 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia (bupivacaine 0.25% and fentanyl 2 micrograms/ml, infused at 6-10 ml/h for 76:1.45 h)
Number of subjects: 214
Study 2407144 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 214
Study 2407144 — intervention group
Group type: COMPARATOR
Intervention: Control (standard general anesthesia with piritramid for postoperative pain relief)
Number of subjects: 214
Study 7437747 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas-powered jet injection
Number of subjects: 10
Study 7437747 — intervention group
Group type: COMPARATOR
Intervention: Needle and syringe
Number of subjects: 10
Study 30927229 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-report questionnaire (Swanson, Nolan and Pelham Questionnaire‐IV; SNAP‐IV)
Number of subjects: 0
Study 30927229 — intervention group
Group type: COMPARATOR
Intervention: Clinical judgment (semi-structured parent interview)
Number of subjects: 0
Study 28614910 — intervention group
Group type: EXPERIMENTAL
Intervention: TP53 mutation
Number of subjects: 265
Study 28614910 — intervention group
Group type: COMPARATOR
Intervention: Wild-type TP53
Number of subjects: 265
Study 27476252 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular oxytocin
Number of subjects: 66
Study 27476252 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous oxytocin
Number of subjects: 66
Study 27476252 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous traditional oxytocin infusion
Number of subjects: 66
Study 27476252 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 66
Study 25110677 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone therapy (1 mL of testosterone enanthate 250 mg/mL) once every four weeks for 12 weeks
Number of subjects: 50
Study 25110677 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 mL of 0.9% wt/vol NaCl) once every four weeks for 12 weeks
Number of subjects: 50
Study 22392565 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose chemotherapy (elimination of 2 induction drugs and 3 months of maintenance therapy from the standard regimen)
Number of subjects: 132
Study 22392565 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen from CCG 2891 (DCTER)
Number of subjects: 132
Study 18809309 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteoheparan sulfate coated, hydrophobic silica surface biosensor
Number of subjects: 0
Study 18809309 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern analysis of biomarker molecules from blood samples
Number of subjects: 0
Study 18809309 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of both biosensors
Number of subjects: 0
Study 18809309 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized therapy decision based on diagnostic tools
Number of subjects: 0
Study 17315527 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 32
Study 17315527 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily injections (MDI) of glargine
Number of subjects: 32
Study 15148453 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymyxin B-immobilized fiber (PMX-F) treatment
Number of subjects: 12
Study 11691759 — intervention group
Group type: COMPARATOR
Intervention: School based intervention including teacher training, modification of school meals, and development of school action plans.
Number of subjects: 634
Study 11691759 — intervention group
Group type: COMPARATOR
Intervention: School based intervention
Number of subjects: 634
Study 9478091 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorfenvinphos exposure
Number of subjects: 41
Study 7702797 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-normal blood pressure group
Number of subjects: 283
Study 7702797 — intervention group
Group type: COMPARATOR
Intervention: High-normal blood pressure group
Number of subjects: 283
Study 7702797 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 283
Study 3301155 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (20 or 40 mg t.i.d.)
Number of subjects: 7
Study 31321536 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D HD laparoscopic system
Number of subjects: 120
Study 31321536 — intervention group
Group type: COMPARATOR
Intervention: 4K laparoscopic system
Number of subjects: 120
Study 28927647 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of an osteotome in addition to standard technique to preserve a bone island anterior to the tibial attachment of the PCL
Number of subjects: 60
Study 28927647 — intervention group
Group type: COMPARATOR
Intervention: Standard tibial resection without the use of an osteotome (control group)
Number of subjects: 60
Study 28245853 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised, individualised or physiotherapist-supervised neuromuscular shoulder exercise programme
Number of subjects: 80
Study 28245853 — intervention group
Group type: COMPARATOR
Intervention: Standard care (self-managed shoulder exercise programme)
Number of subjects: 80
Study 26129996 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally Adapted Cognitive-Behavioral Therapy (CA-CBT)
Number of subjects: 50
Study 26129996 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 50
Study 23836044 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic antibiotics (AB) - amoxicillin and metronidazole three times a day for 7 days
Number of subjects: 36
Study 23836044 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) - two applications on the day of SRP and at follow-up after 7 days
Number of subjects: 36
Study 23836044 — intervention group
Group type: COMPARATOR
Intervention: Comparison between AB and PDT
Number of subjects: 36
Study 21185118 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (50-200mg t.i.d.)
Number of subjects: 103
Study 21185118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 21185118 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 103
Study 18503851 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 55
Study 18503851 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (Control)
Number of subjects: 55
Study 12622856 — intervention group
Group type: EXPERIMENTAL
Intervention: Braun Oral-B 3D Plaque Remover
Number of subjects: 35
Study 12622856 — intervention group
Group type: COMPARATOR
Intervention: Butler GUM 311
Number of subjects: 35
Study 9477048 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg OTFC
Number of subjects: 12
Study 9477048 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg OTFC
Number of subjects: 12
Study 9477048 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 microg OTFC
Number of subjects: 12
Study 9477048 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,600 microg OTFC
Number of subjects: 12
Study 8675721 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydipsic patients with marked stereotypies
Number of subjects: 3
Study 8675721 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydipsic patients with no history of stereotypy
Number of subjects: 3
Study 8675721 — intervention group
Group type: COMPARATOR
Intervention: Nonpolydipsic patient
Number of subjects: 3